New biologics in the management of Crohn's disease: focus on certolizumab pegol.

Clin Exp Gastroenterol · 2009 · PMC3108632 · PMID 21694828

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, at week 12 the difference between the certolizumab- and placebo-treated groups did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.